{"title":"抗血管紧张素2受体1抗体（抗at1r）和抗内皮素受体a型（抗etar）作为系统性硬化症（SSc）患者内皮功能障碍的生物标志物","authors":"Chiara Pellicano, Annalisa Villa, Gabriella Cusa, Giancarlo D'Ippolito, Valeria Carnazzo, Federica Laterza, Umberto Basile, Edoardo Rosato, Antonietta Gigante","doi":"10.1080/1744666X.2025.2574659","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Aims of this study were to evaluate the serum level of autoantibodies against G-protein-coupled receptors for Angiotensin II type 1 (anti-AT1R) and endothelin receptor type A (anti-ETAR) in systemic sclerosis (SSc) patients and healthy controls (HC) and to evaluate the associations of these antibodies with microvascular complication of SSc, such as digital ulcers (DUs), subclinical renal vasculopathy and early pulmonary vasculopathy.</p><p><strong>Research design and methods: </strong>Sixty-four SSc patients and 20 HC were tested for anti-AT1R and anti-ETAR.</p><p><strong>Results: </strong>SSc patients had higher anti-AT1R [7.78 ng/ml (IQR 6.14;12.16) vs 3.25 ng/ml (IQR 2.60;4.70), <i>p</i> < 0.001] and anti-ETAR [0.16 OD (IQR 0.14;0.17) vs 0.10 OD (IQR 0.10;0.12), <i>p</i> < 0.001] than HC. SSc patients with DUs had higher anti-AT1R [10.79 ng/ml (IQR 7.32;14.15) vs 6.76 ng/ml (IQR 5.88;7.88), <i>p</i> < 0.001] and anti-ETAR [0.16 OD (IQR 0.15;0.18) vs 0.15 OD (IQR 0.13;0.16), <i>p</i> < 0.01] than SSc patients without DUs. We found a positive correlation between renal resistive index (RRI) and anti-AT1R (<i>r</i> = 0.357, <i>p</i> < 0.01) or anti-ETAR (<i>r</i> = 0.442, <i>p</i> < 0.001) and a negative correlation between tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure (TAPSE/sPAP) and anti-AT1R (<i>r</i> = -0.436, <i>p</i> < 0.001) or anti-ETAR (<i>r</i> = -0.334, <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>Anti-AT1R and anti-ETAR may play a pathogenic role in endothelial dysfunction.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":3.7000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-angiotensin 2 receptor 1 antibody (anti-AT1R) and anti-endothelin receptor type a (anti-ETAR) as biomarkers of endothelial dysfunction in systemic sclerosis (SSc) patients.\",\"authors\":\"Chiara Pellicano, Annalisa Villa, Gabriella Cusa, Giancarlo D'Ippolito, Valeria Carnazzo, Federica Laterza, Umberto Basile, Edoardo Rosato, Antonietta Gigante\",\"doi\":\"10.1080/1744666X.2025.2574659\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Aims of this study were to evaluate the serum level of autoantibodies against G-protein-coupled receptors for Angiotensin II type 1 (anti-AT1R) and endothelin receptor type A (anti-ETAR) in systemic sclerosis (SSc) patients and healthy controls (HC) and to evaluate the associations of these antibodies with microvascular complication of SSc, such as digital ulcers (DUs), subclinical renal vasculopathy and early pulmonary vasculopathy.</p><p><strong>Research design and methods: </strong>Sixty-four SSc patients and 20 HC were tested for anti-AT1R and anti-ETAR.</p><p><strong>Results: </strong>SSc patients had higher anti-AT1R [7.78 ng/ml (IQR 6.14;12.16) vs 3.25 ng/ml (IQR 2.60;4.70), <i>p</i> < 0.001] and anti-ETAR [0.16 OD (IQR 0.14;0.17) vs 0.10 OD (IQR 0.10;0.12), <i>p</i> < 0.001] than HC. SSc patients with DUs had higher anti-AT1R [10.79 ng/ml (IQR 7.32;14.15) vs 6.76 ng/ml (IQR 5.88;7.88), <i>p</i> < 0.001] and anti-ETAR [0.16 OD (IQR 0.15;0.18) vs 0.15 OD (IQR 0.13;0.16), <i>p</i> < 0.01] than SSc patients without DUs. We found a positive correlation between renal resistive index (RRI) and anti-AT1R (<i>r</i> = 0.357, <i>p</i> < 0.01) or anti-ETAR (<i>r</i> = 0.442, <i>p</i> < 0.001) and a negative correlation between tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure (TAPSE/sPAP) and anti-AT1R (<i>r</i> = -0.436, <i>p</i> < 0.001) or anti-ETAR (<i>r</i> = -0.334, <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>Anti-AT1R and anti-ETAR may play a pathogenic role in endothelial dysfunction.</p>\",\"PeriodicalId\":12175,\"journal\":{\"name\":\"Expert Review of Clinical Immunology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1744666X.2025.2574659\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2025.2574659","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：本研究的目的是评估系统性硬化症（SSc）患者和健康对照（HC）血清中抗血管紧张素II型（抗at1r）和内皮素受体A型（抗etar）的自身抗体水平，并评估这些抗体与SSc微血管并发症（如数字溃疡（DUs）、亚临床肾血管病变和早期肺血管病变）的关系。研究设计与方法：对64例SSc患者和20例HC患者进行抗at1r和抗etar检测。结果：SSc患者抗at1r较高[7.78 ng/ml (IQR 6.14;12.16) vs 3.25 ng/ml (IQR 2.60;4.70), p p p p r = 0.357, p r = 0.442, p r = - 0.436, p r = - 0.334， p结论：抗at1r和抗etar可能在内皮功能障碍中起致病性作用。
Anti-angiotensin 2 receptor 1 antibody (anti-AT1R) and anti-endothelin receptor type a (anti-ETAR) as biomarkers of endothelial dysfunction in systemic sclerosis (SSc) patients.
Background: Aims of this study were to evaluate the serum level of autoantibodies against G-protein-coupled receptors for Angiotensin II type 1 (anti-AT1R) and endothelin receptor type A (anti-ETAR) in systemic sclerosis (SSc) patients and healthy controls (HC) and to evaluate the associations of these antibodies with microvascular complication of SSc, such as digital ulcers (DUs), subclinical renal vasculopathy and early pulmonary vasculopathy.
Research design and methods: Sixty-four SSc patients and 20 HC were tested for anti-AT1R and anti-ETAR.
Results: SSc patients had higher anti-AT1R [7.78 ng/ml (IQR 6.14;12.16) vs 3.25 ng/ml (IQR 2.60;4.70), p < 0.001] and anti-ETAR [0.16 OD (IQR 0.14;0.17) vs 0.10 OD (IQR 0.10;0.12), p < 0.001] than HC. SSc patients with DUs had higher anti-AT1R [10.79 ng/ml (IQR 7.32;14.15) vs 6.76 ng/ml (IQR 5.88;7.88), p < 0.001] and anti-ETAR [0.16 OD (IQR 0.15;0.18) vs 0.15 OD (IQR 0.13;0.16), p < 0.01] than SSc patients without DUs. We found a positive correlation between renal resistive index (RRI) and anti-AT1R (r = 0.357, p < 0.01) or anti-ETAR (r = 0.442, p < 0.001) and a negative correlation between tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure (TAPSE/sPAP) and anti-AT1R (r = -0.436, p < 0.001) or anti-ETAR (r = -0.334, p < 0.01).
Conclusions: Anti-AT1R and anti-ETAR may play a pathogenic role in endothelial dysfunction.
期刊介绍：
Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.
Articles focus on the following key areas:
• Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines
• Performance and benefits of newly approved therapeutic agents
• New diagnostic approaches
• Screening and patient stratification
• Pharmacoeconomic studies
• New therapeutic indications for existing therapies
• Adverse effects, occurrence and reduction
• Prospects for medicines in late-stage trials approaching regulatory approval
• Novel treatment strategies
• Epidemiological studies
• Commentary and comparison of treatment guidelines
Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
